Salix is committed to helping physicians and patients effectively manage HE.
Read through the information below for more on Salix programs, education opportunities, and links.
Salix is committed to helping HE healthcare providers and their patients effectively address the complexities of HE management through H.E.L.P. —the Hepatic Encephalopathy Living Program.
Benefits include:
Click to watch the video below and discover all the unique benefits that H.E.L.P. brings to both patients and healthcare providers.
To enroll:
3-Step Xifaxan 550 mg reimbursement:
Step 1: Download and fill out the Patient Information Form![]()
To download the form in Word (.doc) format, click here
For instructions on how to fill out the form, click here![]()
Step 2: Call 1-866-XIFAXAN (943-2926) to connect to the Xifaxan 550 mg Reimbursement Helpline.
This free support service connects your office and patients to trained reimbursement analysts to answer questions you may have, and to help negotiate appeals should your patients’ claims be denied. Open Monday–Friday, 8:30 AM–5:30 PM
The helpline can also provide a timely solution to address issues you may encounter, including:
Step 3: Submit your completed Patient Information Form to the Xifaxan 550 mg Reimbursement Fax Line 1-800-387-5807
If you would like a sales representative to discuss our Rebate Card Program with you, please call us at 1-866-669-SLXP (7597).
Back to topFollow these 3 steps to download an ePrint of the New England Journal of Medicine March 2010 article “Rifaximin Treatment in Hepatic Encephalopathy” on Xifaxan 550 mg pivotal phase 3 trial data. Please note that the NEJM ePrint is only supported on the PC platform.
Step 1: Download the file by clicking on the link provided below.
Step 2: Click the "Save" button. You will be prompted to either "Run" or "Save" the ePrint file. We recommend you save the ePrint file to a location on your computer where you can locate it and activate it at a later time.
Step 3: Locate the file on your computer and double-click to open. To open the saved ePrint file, simply double-click on the file icon you saved to your computer. You must be connected to the Internet the first time you open the ePrint.
Download the article now Back to topWatch the webcast "Treatment of HE: Reducing the Risk of Breakthrough Episodes." This dynamic Product Theater presentation will highlight the first new therapy for hepatic encephalopathy (HE) in 30 years, Xifaxan 550 mg.
Introduction to Xifaxan 550 mg by Steven L. Flamm, MD
Background on hepatic encephalopathy by Robert S. Brown, Jr, MD, MPH
Phase 3 trial by Fred Poordad, MD
Case studies by Steven L. Flamm, MD
Salix Pharmaceuticals is not responsible for the content of any external web sites. By linking to external web sites, Salix Pharmaceuticals does not intend to imply that it endorses these organizations, nor does it imply an endorsement of Salix Pharmaceuticals or any of its products by these organizations.
Back to topSalix provides a team of medical experts and liaisons for its physician customers. If you still have questions about Xifaxan 550 mg that have not been answered on this website, please call us at 1-866-669-SLXP (7597).
If you would like to receive future information about Xifaxan 550 mg along with updates to the Xifaxan 550 mg website, please sign up for updates.
XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).
Complete Prescribing Information.![]()
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: Salix@medcomsol.com
Use of this site signifies your agreement to the Terms of Use and Legal Restrictions. Privacy Policy.
©2010 Salix Pharmaceuticals, Inc. All rights reserved. RIF 10/44
1700 Perimeter Park Drive, Morrisville, NC 27560-8404 U.S.A. T: 866-669-SLXP (7597), F: 919-862-1095